Compare REAX & CTKB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | REAX | CTKB |
|---|---|---|
| Founded | 2018 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 792.1M | 652.1M |
| IPO Year | 2021 | 2021 |
| Metric | REAX | CTKB |
|---|---|---|
| Price | $2.44 | $4.32 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 4 | 5 |
| Target Price | $5.55 | ★ $5.70 |
| AVG Volume (30 Days) | ★ 1.8M | 658.1K |
| Earning Date | 01-01-0001 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $193,015,000.00 |
| Revenue This Year | $21.82 | $5.02 |
| Revenue Next Year | $18.31 | $7.89 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 17.67 |
| 52 Week Low | $2.45 | $2.37 |
| 52 Week High | $5.41 | $6.18 |
| Indicator | REAX | CTKB |
|---|---|---|
| Relative Strength Index (RSI) | 31.76 | 39.65 |
| Support Level | N/A | $4.00 |
| Resistance Level | $4.42 | $5.24 |
| Average True Range (ATR) | 0.18 | 0.22 |
| MACD | 0.02 | 0.02 |
| Stochastic Oscillator | 6.14 | 42.41 |
The Real Brokerage Inc is a technology-powered real estate brokerage firm located in the United States and Canada. It has developed a proprietary transaction management and brokerage operations software called reZEN, which powers nearly all of its brokerage operations, enabling efficiency, automation, and flexibility by incorporating end-to-end transaction management, automated compliance and brokerage oversight, integrated payments and financial services, Leo CoPilot, and open API for customization. In addition, the company also offers mortgage brokering and title services. The company's operating segments are North American Brokerage, which derives key revenue, One Real Title, One Real Mortgage, and Real Wallet. Geographically, it derives key revenue from the United States.
Cytek Biosciences Inc is a cell analysis solutions company advancing the next generation of cell analysis tools by leveraging novel technical approaches. Its core instruments, the Cytek Aurora and Northern Lights systems, are the first full-spectrum flow cytometers able to deliver high-resolution, high-content, and high-sensitivity cell analysis by utilizing the full spectrum of fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells. Its FSP platform addresses the inherent limitations of other technologies by providing a higher density of information with greater sensitivity, more flexibility, and increased efficiency, all at a lower cost for performance. Geographically, the company generates a majority of its revenue from the United States.